Based on these studies (Alonso-Nocelo et al., 2023; Kim et al., 2024; Li et al., 2021) and our results, we believe that combination therapy targeting PARP9 and LOXL2 may be a promising strategy for the treatment of advanced and metastatic PC. This evidence concerns the gene PARP9 and pachyonychia congenita.